Mary Alder, NP
Nurse Practitioner · Washington, DCNPI 1548450463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Gilead at 42.9% of the total. Reporting peaked in 2022 at $1,199 and has fallen 74.3% since, to $308 in 2025. Among nurse practitioner clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$1K
- AbbVie$241
- Johnson & Johnson$141
- Biohaven Pharmaceutical Holding Company Ltd.$113
- Janssen Products, LP$87
- plus $315 from 10 others
What the payments were for
- Food & beverage$3,84798%
- Education$872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 70 | $1,689 |
| Viiv Healthcare Company | 61 | $1,348 |
| AbbVie | 9 | $241 |
| Johnson & Johnson | 7 | $141 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $113 |
| Janssen Products, LP | 1 | $87 |
| Novo Nordisk | 4 | $80 |
| Theratechnologies Inc. | 3 | $75 |
| Napo Pharmaceuticals Inc | 2 | $37 |
| Lilly USA, LLC | 1 | $24 |
| Bayer | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,934 in reported general payments places this provider in the 95th percentile of 224 nurse practitioner providers in District of Columbia.
See all nurse practitioner providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 25 | $132,432 |
| DovatoDolutegravir Sodium/Lamivudine | 14 | $41,834 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $25,899 |
| OzempicSemaglutide | 18 | $24,650 |
| EvotazAtazanavir Sulfate/Cobicistat | 12 | $18,880 |
| MounjaroTirzepatide | 12 | $12,955 |
| TrulicityDulaglutide | 12 | $11,430 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $10,525 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $8,179 |
| JardianceEmpagliflozin | 12 | $6,274 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,067 |
| Nebivolol Hcl | 12 | $993 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $874 |
| Rosuvastatin Calcium | 41 | $652 |
| AbacavirAbacavir Sulfate | 12 | $633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,689 | $158,33137 claims |
| Viiv Healthcare CompanyDovato | $1,348 | $41,83414 claims |
| Novo NordiskOzempic | $80 | $24,65018 claims |
| Lilly USA, LLCMounjaro, Trulicity | $24 | $24,38524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 224 nurse practitioner providers in District of Columbia.
Other nurse practitioner in Washington
- Rasheda PersingerWashington$88K
- Caitlin YazelWashington$45K
- Aimee LestrangeWashington$37K
- Guinevere QueWashington$27K
- Cynthia BitherWashington$17K
- Safia AbdillahiWashington$11K
- Brigid ReynoldsWashington$6K
- Odette NtamWashington$5K
- Kathryn HilgartnerWashington$5K
- Joseph HugginsWashington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.